<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty-eight <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) patients were treated with <z:chebi fb="0" ids="30621">arsenic trioxide</z:chebi> (ATO) and thalidomide </plain></SENT>
<SENT sid="1" pm="."><plain>Seven patients responded including one complete hematologic and cytogenetic response and one with regression in spleen size </plain></SENT>
<SENT sid="2" pm="."><plain>Two trilineage responses were seen in patients with inv(3)(q21q26.2) </plain></SENT>
<SENT sid="3" pm="."><plain>Three of five patients who had high pre-therapy EVI1 levels showed unexpectedly good responses while two died early in the first cycle </plain></SENT>
<SENT sid="4" pm="."><plain>In vitro studies using 32Dcl3 cells forced to express EVI1 confirmed increased sensitivity of these cells to ATO </plain></SENT>
<SENT sid="5" pm="."><plain>Both low/high risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> may benefit significantly from therapy with ATO/thalidomide, and those with high pre-therapy EVI1 expression may be uniquely sensitive </plain></SENT>
</text></document>